Hydroxychloroquine is now available to our physicians to continue to treat their patients. Since hydroxychloroquine has been introduced as a possible treatment for COVID-19 supplies have been significantly depleted. Although the drug has not been scientifically tested for the treatment of COVID-19 it is being used to treat those that are not responding to other therapeutic approaches. It is not recommended that hydroxychloroquine be used to treat COVID-19 unless a doctor is directly administering the treatment.
Lupus and Rheumatoid Arthritis Patients May Suffer
Unfortunately, many patients that are currently being treated for lupus erythematosus and rheumatoid arthritis are finding it difficult to get hydroxychloroquine. The mechanism of action is unkown for these diseases. The drug was approved by the FDA in 1955 and has a good safety profile. Side effects include irritability, nausea, dizziness headache, muscle pain, rash and itching. It can lead to reduced white blood cells or platelets and anemia. A rare but very serious eye toxicity can occur that can lead to loss of vision and color blindness. Therefore it is imperative that regular eye examines are scheduled with an opthalmologist.
Hydroxychloroquine is typically prescribed for all patients with lupus that do not have a contraindication for the drug. It effectively relieves musculoskeletal, constitutional and mucocutanieous manifestations and decreases organ damage and mortality. Additionally, hydroxychloroquine reduces flares and helps maintain disease remission. 80% of patients with lupus that is not organ threatening achieve remission with hydroxychloroquine and can sustain remission with therapy for long periods.
During the COVID-19 pandemic it is important that lupus and rheumatoid arthritis patients continue to have regular access to hydroxychloroquine. Access will reduce the chance of flare ups and the need for corticosteroids which further compromise the immune system. Leading to the increased likelihood of possible infection with a virus such as COVID-19.
If you are a physician and would like to have access to hydroxychloroquine please contact our office and discuss your options. We have a limited supply of this drug available.
References
Ruiz-Irastorza G , Ramos-Casals M , Brito-Zeron P , Khamashta MA . Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28. doi:10.1136/ard.2008.101766
